|
N.G. Afanasyeva (1, 2), A.V. Vazhenin (1, 2), L.Yu. Trofimchuk (1), K.V. Chvanova (1)
Sentinel lymph node scintigraphy in breast cancer. Own experience
|
№7 / 2021
|
|
V.F. Semiglazov (1, 2), R.S. Pesotsky (1), A.I. Tseluiko (1), M.A. Dzhelyalova (1), V.S. Apollonova (1), V.V. Semiglazov (1, 3)
Search for new prognostic and predictive markers of sensitivity to endocrine therapy, chemotherapy and immunotherapy of breast cancer
|
№7 / 2021
|
|
M.A. Dzhelyalova, V.F. Semiglazov
Endocrine resistance in breast cancer treatment
|
№11 / 2020
|
|
V.F. Semiglazov, M.A. Dzhelyalova, A.I. Tseluyko, R.S. Pesotsky, A.A. Bessonov, T.Yu. Semiglazova
Neoadjuvant and postneoadjuvant treatment for triple negative breast cancer
|
№11 / 2020
|
|
P.V. Kazantseva (1), E.M. Slonimskaya (1, 2), M.M. Tsyganov (1), M.K. Ibragimova (1, 3), A.V. Doroshenko (1), N.A. Tarabanovskaya (1), N.V. Litviakov (1, 3)
Predictive and prognostic significance of stemness gene amplifications in the breast tumor in patients who received neoadjuvant chemotherapy
|
№7 / 2019
|
|
P.I. Shabalkin
ANALYSIS OF INFLUENCE ON THE BUDGET OF THE RUSSIAN FEDERATION OF THE USE OF ORAL VINORELBINE FOR THE TREATMENT OF METASTATIC BREAST CANCER
|
№7 / 2018
|
|
E.M. Slonimskaya (1, 2), P.V. Kazantseva (1), N.V. Litviakov (1, 3), M.M. Tsyganov (1), M.K. Ibragimova (1, 3), A.V. Doroshenko (1), R.U. Vernadsky (1), M.A. Vostrikova (2), N.A. Lushnikova (2)
EXPERIENCE OF PERSONALIZED APPOINTMENT OF NEOADJUVANT CHEMOTHERAPY FOR PATIENT WITH BREAST CANCER: A PROSPECTIVE STUDY
|
№7 / 2018
|
|
V.F. Semiglazov, G.A. Dashyan, P.V. Krivorotko, R.M. Paltuev, R.V. Donskikh, T.Yu. Semiglazova, K.Y. Zernov, L.P. Gigolaeva, V.S. Apollonova
NEW POSSIBILITIES OF THE TREATMENT OF BREAST CANCER: MICROTUBULE INHIBITORS
|
№17 / 2017
|
|
E.V. Lubennikova, L.G. Zhukova, E.A. Arutyunyan
IXEMPRA - NEW POSSIBILITIES OF CYTOSTATIC THERAPY OF BREAST CANCER
|
№8 / 2017
|
|
S.L. Gutorov, E.I. Borisova, M.E. Abramov, A.N. Lud, E.A. Arutyunyan
NON-SMALL LUNG CANCER. EXPANDING THERAPEUTIC OPPORTUNITIES: PEMBROLIZUMAB IN A NUMBER OF MALIGNANT TUMORS
|
№8 / 2017
|
|
V.F. Semiglazov (1), G.A. Dashyan (1), V.V. Semiglazov (2), R.M. Paltuev (1), T.Yu. Semiglazova (1), R.V. Donskikh (1), K.S. Nikolaev (1), A.V. Komyakhov (1), K.Yu. Zernov (1), P.V. Krivorotko (1)
TAXANES IN THE TREATMENT OF BREAST CANCER
|
№17 / 2016
|
|
L.G. Zhukova, A.G. Manikhas
FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
|
№17 / 2016
|
Русский
